[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2017015293A - Composicion para tratar lesiones tisulares. - Google Patents

Composicion para tratar lesiones tisulares.

Info

Publication number
MX2017015293A
MX2017015293A MX2017015293A MX2017015293A MX2017015293A MX 2017015293 A MX2017015293 A MX 2017015293A MX 2017015293 A MX2017015293 A MX 2017015293A MX 2017015293 A MX2017015293 A MX 2017015293A MX 2017015293 A MX2017015293 A MX 2017015293A
Authority
MX
Mexico
Prior art keywords
tissue lesions
present
composition
association
treatment
Prior art date
Application number
MX2017015293A
Other languages
English (en)
Inventor
Barritault Denis
Original Assignee
Organes Tissus Regeneration Reparation Remplacement Otr3
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organes Tissus Regeneration Reparation Remplacement Otr3 filed Critical Organes Tissus Regeneration Reparation Remplacement Otr3
Publication of MX2017015293A publication Critical patent/MX2017015293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que incluye un polímero biocompatible en asociación con una célula eucariota, un extracto y/o lisado plaquetario o un factor de crecimiento, para utilizarse como un medicamento para la prevención y/o tratamiento de lesiones tisulares. La presente invención también se refiere a un kit farmacéutico que comprende un polímero biocompatible en asociación con una célula eucariota para la prevención y/o el tratamiento de lesiones tisulares. La presente invención se refiere igualmente al uso de una composición farmacéutica que comprende un polímero biocompatible en asociación con una célula eucariota, un extracto y/o lisado plaquetario o un factor de crecimiento, para la fabricación de un medicamento para el tratamiento de lesiones tisulares. La presente invención se puede usar particularmente en los campos veterinario y farmacéutico.
MX2017015293A 2015-05-28 2016-05-26 Composicion para tratar lesiones tisulares. MX2017015293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305807.8A EP3097922A1 (fr) 2015-05-28 2015-05-28 Composition pour le traitement des lesions tissulaires
PCT/EP2016/061906 WO2016189088A1 (fr) 2015-05-28 2016-05-26 Composition pour le traitement des lesions tissulaires

Publications (1)

Publication Number Publication Date
MX2017015293A true MX2017015293A (es) 2018-05-02

Family

ID=53269418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015293A MX2017015293A (es) 2015-05-28 2016-05-26 Composicion para tratar lesiones tisulares.

Country Status (17)

Country Link
US (1) US11351190B2 (es)
EP (3) EP3097922A1 (es)
JP (1) JP7554033B2 (es)
KR (1) KR20180044235A (es)
CN (1) CN107809999A (es)
AU (1) AU2016266773B2 (es)
CA (1) CA2987547A1 (es)
DK (1) DK3302523T3 (es)
ES (1) ES2755055T3 (es)
IL (1) IL255694B (es)
MX (1) MX2017015293A (es)
PL (1) PL3302523T3 (es)
PT (1) PT3302523T (es)
RU (1) RU2721116C2 (es)
SI (1) SI3302523T1 (es)
WO (1) WO2016189088A1 (es)
ZA (1) ZA201707813B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112261944A (zh) 2018-06-05 2021-01-22 Medipost株式会社 用于治疗软骨损伤相关疾病的包含透明质酸和干细胞的药物组合物
EP3689327A1 (fr) * 2019-01-24 2020-08-05 Organes Tissus Régénération Réparation Remplacement Composition pharmaceutique dans le traitement de lésions pulmonaires
FR3096579B1 (fr) * 2019-05-27 2023-05-05 Organes Tissus Regeneration Reparation Remplacement composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
CN110755597B (zh) * 2019-10-24 2023-07-07 广州市希丽生物科技服务有限公司 用于预防和治疗类风湿性关节炎的外用药物组合物
AU2021235223A1 (en) * 2020-03-09 2022-09-29 Denis Barritault Composition for the treatment of lesions of the respiratory system

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
FR2718023B1 (fr) 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
FR2718025B1 (fr) 1994-03-30 1996-06-21 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement des lésions du système nerveux.
FR2781485B1 (fr) * 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
RU2132187C1 (ru) * 1998-11-12 1999-06-27 Антипов Борис Геннадиевич Способ лечения заболеваний кожи и слизистых оболочек и магнитоактивное органическое соединение железа, используемое в нем
US6361985B1 (en) 1999-01-12 2002-03-26 Zymogenetics, Inc. Beta-1,3-galactosyltransferase homolog, ZNSSP6
FR2794649B1 (fr) * 1999-06-11 2003-04-11 Solutions Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications
EP1513404A4 (en) 2002-05-30 2006-01-04 Myocardial Therapeutics Inc INTRAMYOCARDIAL INJECTIONS OF AUTOLOGOUS BONE MARROW
FR2861308A1 (fr) 2003-10-28 2005-04-29 Organes Tissus Regeneration Re Utilisation de polymeres biocompatibles pour la preparation d'une composition pharmaceutique, dermatologique ou cosmetique destinee a la prevention, au soulagement ou au traitement des genes, desagrements et douleurs
US20060257449A1 (en) 2005-05-16 2006-11-16 Didier Billy Methods, compositions, systems, and devices for bone fusion
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
BRPI0805852A8 (pt) 2008-09-05 2021-06-29 Univ Rio De Janeiro polímeros ácidos protéicos, processos de produção, uso de polímeros ácidos protéicos, composição farmacêutica e método de tratamento
CA2851761C (en) * 2011-10-14 2021-06-15 Centre National De La Recherche Scientifique Method of diagnosis, prognostic or treatment of neurodegenerative diseases
EP3097928A1 (fr) * 2015-05-28 2016-11-30 Organes Tissus Régénération Réparation Remplacement Composition pour le traitement des lesions cerebrales

Also Published As

Publication number Publication date
EP3097922A1 (fr) 2016-11-30
IL255694B (en) 2021-02-28
CN107809999A (zh) 2018-03-16
RU2721116C2 (ru) 2020-05-15
RU2017140049A (ru) 2019-06-28
EP3302523A1 (fr) 2018-04-11
PT3302523T (pt) 2019-11-05
WO2016189088A1 (fr) 2016-12-01
SI3302523T1 (sl) 2019-12-31
PL3302523T3 (pl) 2020-03-31
KR20180044235A (ko) 2018-05-02
RU2017140049A3 (es) 2019-08-27
EP3626256C0 (fr) 2023-08-09
ZA201707813B (en) 2018-12-19
AU2016266773A1 (en) 2017-12-21
AU2016266773B2 (en) 2022-01-06
ES2755055T3 (es) 2020-04-21
JP7554033B2 (ja) 2024-09-19
JP2018520115A (ja) 2018-07-26
EP3302523B1 (fr) 2019-09-11
CA2987547A1 (fr) 2016-12-01
DK3302523T3 (da) 2019-11-04
IL255694A (en) 2018-01-31
US11351190B2 (en) 2022-06-07
EP3626256B1 (fr) 2023-08-09
US20180125880A1 (en) 2018-05-10
EP3626256A1 (fr) 2020-03-25

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
NZ733174A (en) Quinazoline derivatives used to treat hiv
CA2956871C (en) Compounds active towards bromodomains
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017015293A (es) Composicion para tratar lesiones tisulares.
PH12016502352A1 (en) Pharmaceutical composition
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
MX2018008646A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2018006226A (es) Agente estimulador del receptor 1b de 5-hidroxitriptamina para mejorar el potencial de injerto in vivo.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IL249860A0 (en) Pharmaceutical preparations, methods for their preparation and their use for the treatment of cancer
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
MX2018003313A (es) Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.